ACRS · Aclaris Therapeutics, Inc.
$5.78
-0.08 (-1.37%)
At close · Aug 14
Market Cap
$850.81M
Shares
147.20M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$5.78
Open$5.82
Day$5.64–5.86
52W close$1.69–6.36
Avg vol 30d1.8M
Short int13.8M · 9.4% float · 8.7d
Short vol52%
Last earningsMay 7, 2026
DataJan 2020–Aug 2026
Filing10-Q · Aug 6
Up next
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed Aug 6, 2026
Equibles Rating
blended score · not investment adviceOverall
Buy
SellHoldBuy
Technical
Buy
Momentum
Very Strong
Sentiment
Neutral
Fundamentals
Strong
Quant / Vol
Very High
Market backdrop
VIX 14.3 · calm
Equity put/call 0.52
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+47%
above
Price vs 50-day avg
+10%
above
RSI (14)
54
neutral
MACD trend
Negative
52-week position
88%
near high
Momentum
relative strength
1-month return
+2%
trailing
6-month return
+78%
trailing
YTD return
+92%
this year
Relative strength
+64%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $5 › 200d $4 — 50d above 200d
Institutional flow
Accumulating
+7% holders QoQ · +28 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
9.36% of float · ▲ +3.1% MoM · 8.7 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
147 holders — near 3-yr high, broad support
Squeeze score
68
elevated · 0–100
Fundamentals
Gross margin
193%
EPS growth
+69%
Y/Y
Free cash flow
$-47.2M
Balance sheet
$9.3M
net cash
Quant / Vol
risk profile
Volatility
97%
annualized · 1-yr
Max drawdown
−37%
past year
ATR
5.7%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Buy
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+47%
Bullish
Price vs 50-day avg
+10%
Bullish
RSI (14)
54
Neutral
MACD trend
Negative
Bearish
52-week position
88%
Bullish
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross)
No cross
50d $5 › 200d $4 — 50d above 200d
Institutional flow
Accumulating
+7% holders QoQ · +28 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
9.36% of float · ▲ +3.1% MoM · 8.7 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
147 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $2
Now $6 · 88%
Range high $6
vs 200-day avg +47%
vs 50-day avg +10%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
ACRS
this stock
Aclaris Therapeutics, Inc.
|
$850.81M | +92.0% | -58.2% | — | 9.4% |
|
ONC
BeOne Medicines Ltd.
|
$513.62B | +14.4% | +22179.2% | 789.7 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$128.19B | +11.6% | +46.2% | 29.5 | 1.6% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$82.72B | +4.1% | +20.8% | 19.9 | 3.3% |
|
ARGX
Argenx SE
|
$52.94B | +1.2% | — | — | 2.1% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| ACRS | -2.2% | +1.8% | +77.9% | +11.2% | +92.0% |
| SPY | +0.4% | +4.5% | +13.8% | +3.9% | +13.9% |
| vs SPY | -2.6% | -2.7% | +64.1% | +7.2% | +78.2% |
Key facts
CIK
1557746
CUSIP
00461U105
13F (30d)
144 filings
142 filers
Visit website
Investor relations